AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21478734 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV (noninvasive positive pressure ventilation)
Number of subjects: 66
Study 21478734 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV + RM (noninvasive positive pressure ventilation followed by recruitment maneuver)
Number of subjects: 66
Study 21478734 — intervention group
Group type: COMPARATOR
Intervention: CON (conventional preoxygenation with spontaneous breathing of 100% O₂)
Number of subjects: 66
Study 21478734 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 66
Study 21478734 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV + RM
Number of subjects: 66
Study 19451404 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg single dose
Number of subjects: 44
Study 16934728 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 43
Study 16934728 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 43
Study 15252193 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam 1 mg at bedtime for one week followed by 2 mg at bedtime for one week
Number of subjects: 6
Study 15252193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 10904465 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin sodium (extended out-of-hospital prophylaxis for 35 days)
Number of subjects: 569
Study 10904465 — intervention group
Group type: COMPARATOR
Intervention: In-hospital warfarin/out-of-hospital placebo
Number of subjects: 569
Study 9060195 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour transdermal nicotine patch
Number of subjects: 100
Study 9060195 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 100
Study 9060195 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained abstainers
Number of subjects: 100
Study 8359959 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported snoring
Number of subjects: 1504
Study 8359959 — intervention group
Group type: EXPERIMENTAL
Intervention: RDI >= 5
Number of subjects: 1504
Study 8359959 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported snores
Number of subjects: 1504
Study 2943049 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms
Number of subjects: 21
Study 2943049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 2 mg
Number of subjects: 21
Study 2943049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 28858412 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 5 mg
Number of subjects: 600
Study 28858412 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 600
Study 28858412 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 600
Study 28858412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 27070089 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 10074
Study 27070089 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 10074
Study 27070089 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 10074
Study 25486675 — intervention group
Group type: COMPARATOR
Intervention: Computer tailoring
Number of subjects: 393
Study 25486675 — intervention group
Group type: COMPARATOR
Intervention: Health counseling
Number of subjects: 393
Study 22762942 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban 15 mg bid
Number of subjects: 0
Study 22762942 — intervention group
Group type: COMPARATOR
Intervention: Mechanical prophylaxis
Number of subjects: 0
Study 20697307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored newsletters
Number of subjects: 225
Study 20697307 — intervention group
Group type: COMPARATOR
Intervention: Generic newsletters
Number of subjects: 225
Study 18683717 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative computer-aided design (CAD) system
Number of subjects: 182
Study 18683717 — intervention group
Group type: COMPARATOR
Intervention: Traditional preoperative templating
Number of subjects: 182
Study 15735186 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant total contact cast (iTCC)
Number of subjects: 50
Study 15735186 — intervention group
Group type: COMPARATOR
Intervention: Removable cast walker (RCW)
Number of subjects: 50
Study 12928815 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT), 5 times a week for 6 weeks
Number of subjects: 86
Study 12928815 — intervention group
Group type: COMPARATOR
Intervention: Standard decubitus care (control)
Number of subjects: 86
Study 12928815 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 86
Study 12928815 — intervention group
Group type: EXPERIMENTAL
Intervention: Norton scores
Number of subjects: 86
Study 10510109 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine (15 mg three times daily)
Number of subjects: 366
Study 10510109 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin (5 mg twice daily)
Number of subjects: 366
Study 10510109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study 10510109 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine
Number of subjects: 366
Study 10510109 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 366
Study 10510109 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of efficacy
Number of subjects: 366
Study 8683844 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐agonist therapy after drainage of endometrioma for 6 months
Number of subjects: 26
Study 8683844 — intervention group
Group type: COMPARATOR
Intervention: GnRH‐agonist therapy alone for 6 months
Number of subjects: 26
Study 1984619 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive home and ambulatory program for pediatric asthma management including 3-month clinic visits, education, and home visits by a specially trained research nurse.
Number of subjects: 95
Study 1984619 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive home and ambulatory program for pediatric asthma management.
Number of subjects: 95
Study 1984619 — intervention group
Group type: COMPARATOR
Intervention: Regular care from a family physician or pediatrician (Control).
Number of subjects: 95
Study 6524855 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible choledochoscopy
Number of subjects: 197
Study 6524855 — intervention group
Group type: COMPARATOR
Intervention: Postexploratory T‐tube cholangiography
Number of subjects: 197
Study 6524855 — intervention group
Group type: COMPARATOR
Intervention: No postexploratory control
Number of subjects: 197
Study 30947755 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 61
Study 30947755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 29534070 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program on foot self-care behaviour
Number of subjects: 76
Study 29534070 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 76
Study 27265353 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral co-trimoxazole prophylaxis (120 mg/day for <6 months, 240 mg/day for 6 months to 5 years)
Number of subjects: 1778
Study 27265353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1778
Study 27265353 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral co-trimoxazole prophylaxis
Number of subjects: 1778
Study 24251726 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote past left ventricular ejection fraction (RP‐LVEF)
Number of subjects: 25
Study 24251726 — intervention group
Group type: EXPERIMENTAL
Intervention: RP‐LVEF ≥ 43.5%
Number of subjects: 25
Study 24251726 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic QRS width, septal‐posterior wall motion delay, or tissue Doppler‐derived dyssynchrony indexes
Number of subjects: 25
Study 22285724 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (mean final dose = 1.38 mg/kg)
Number of subjects: 271
Study 22285724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 22285724 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (mean final dose = 1.21 mg/kg)
Number of subjects: 271
Study 22285724 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 271
Study 19652932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiotherapy (7.0 Gy) and indomethacin for 15 days
Number of subjects: 96
Study 19652932 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin alone for 15 days
Number of subjects: 96
Study 19652932 — intervention group
Group type: COMPARATOR
Intervention: Historical control group receiving indomethacin alone
Number of subjects: 96
Study 16998214 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment (mainly atorvastatin) in Group A
Number of subjects: 712
Study 16998214 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment in Group B
Number of subjects: 712
Study 16998214 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment in Group C (without MetS)
Number of subjects: 712
Study 16998214 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment in Group D (without MetS)
Number of subjects: 712
Study 15237767 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (800 mg/d)
Number of subjects: 112
Study 15237767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 12395977 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 10
Study 12395977 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 9804507 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 125
Study 9804507 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluoperazine (TFP)
Number of subjects: 125
Study 9804507 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (VER)
Number of subjects: 125
Study 9804507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (MAN)
Number of subjects: 125
Study 9804507 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 125
Study 7700960 — intervention group
Group type: EXPERIMENTAL
Intervention: De-nicotinized cigarette (de-nic)
Number of subjects: 7
Study 7700960 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cigarette
Number of subjects: 7
Study 7700960 — intervention group
Group type: COMPARATOR
Intervention: Regular cigarette and de-nic cigarette
Number of subjects: 7
Study 2717287 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (pacifier for 30 minutes with each feeding, 12 times per day until weight of 1,500 g, then 8 times per day)
Number of subjects: 18
Study 2717287 — intervention group
Group type: COMPARATOR
Intervention: Control (no pacifier)
Number of subjects: 18
Study 2717287 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (in subgroup of boys)
Number of subjects: 18
Study 2717287 — intervention group
Group type: COMPARATOR
Intervention: Control (in subgroup of boys)
Number of subjects: 18
Study 1098832 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of folic acid daily
Number of subjects: 9
Study 1098832 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of folic acid daily
Number of subjects: 9
Study 1098832 — intervention group
Group type: COMPARATOR
Intervention: 0 mg of folic acid after dialysis
Number of subjects: 9
Study 1098832 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of folic acid after dialysis
Number of subjects: 9
Study 31870188 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab
Number of subjects: 0
Study 31870188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30636184 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholemeal rye bread (WMR)
Number of subjects: 9
Study 30636184 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat bread (WB)
Number of subjects: 9
Study 28534200 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloading using the Hephaistos orthosis
Number of subjects: 12
Study 28534200 — intervention group
Group type: COMPARATOR
Intervention: Control leg (no unloading)
Number of subjects: 12
Study 26906426 — intervention group
Group type: EXPERIMENTAL
Intervention: Active familiarization (listeners heard audio recordings of words while viewing the written material of words)
Number of subjects: 120
Study 26906426 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive familiarization (listeners heard audio recordings of words)
Number of subjects: 120
Study 26906426 — intervention group
Group type: COMPARATOR
Intervention: Control condition (listeners had no exposure to the audio signal prior to identification tasks)
Number of subjects: 120
Study 23510124 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg once daily for 90 days
Number of subjects: 86
Study 23510124 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 90 days
Number of subjects: 86
Study 21574975 — intervention group
Group type: EXPERIMENTAL
Intervention: wIRA + VIS
Number of subjects: 51
Study 21574975 — intervention group
Group type: COMPARATOR
Intervention: VIS alone
Number of subjects: 51
Study 17934999 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail Making Test (TMT) part A
Number of subjects: 643
Study 17934999 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail Making Test (TMT) part B
Number of subjects: 643
Study 16791015 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 352
Study 15587537 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal block and ring block in combination with concentrated oral sucrose
Number of subjects: 0
Study 15587537 — intervention group
Group type: COMPARATOR
Intervention: Concentrated oral sucrose alone
Number of subjects: 0
Study 15587537 — intervention group
Group type: COMPARATOR
Intervention: No analgesia
Number of subjects: 0
Study 11717622 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral beta(2)-adrenergic receptor agonists (beta(2)-AG)
Number of subjects: 74
Study 11717622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of oral beta(2)-adrenergic receptor agonists (beta(2)-AG) for 2 weeks
Number of subjects: 74
Study 11717622 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion with heart rate adjusted to 90 beats/min
Number of subjects: 74
Study 11717622 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers without heart or pulmonary diseases (control group)
Number of subjects: 74
Study 11717622 — intervention group
Group type: COMPARATOR
Intervention: Patients without beta(2)-adrenergic receptor agonists (group B)
Number of subjects: 74
Study 9137794 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HDAC: 3000 mg/sqm every 12 hours as one-hour infusion for six days)
Number of subjects: 137
Study 9137794 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cytarabine (SDAC: 100 mg/sqm 24 hours infusion over seven days)
Number of subjects: 137
Study 9137794 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HDAC)
Number of subjects: 137
Study 9137794 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cytarabine (SDAC)
Number of subjects: 137
Study 7944756 — intervention group
Group type: EXPERIMENTAL
Intervention: Single layer of continuous absorbable monofilament (Maxon)
Number of subjects: 42
Study 7944756 — intervention group
Group type: COMPARATOR
Intervention: Single layer of interrupted Polyglactin sutures (Vicryl)
Number of subjects: 42
Study 3595574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (single-dose method)
Number of subjects: 0
Study 3595574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (cumulative-dose method)
Number of subjects: 0
Study 3595574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine (single-dose method)
Number of subjects: 0
Study 3595574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine (cumulative-dose method)
Number of subjects: 0
Study 29656977 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Number of subjects: 80
Study 29656977 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain Bupivacaine
Number of subjects: 80
Study 29656977 — intervention group
Group type: COMPARATOR
Intervention: Historical Controls
Number of subjects: 80
Study 29122108 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Up intervention
Number of subjects: 266
Study 29122108 — intervention group
Group type: COMPARATOR
Intervention: Non-insulin-treated T2DM
Number of subjects: 266
Study 29122108 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (insulin initiators and non-initiators)
Number of subjects: 266
Study 26222057 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX-B plus cetuximab
Number of subjects: 755
Study 26222057 — intervention group
Group type: COMPARATOR
Intervention: CAPOX-B
Number of subjects: 755
Study 23122211 — intervention group
Group type: COMPARATOR
Intervention: Peanut Butter (PB)
Number of subjects: 15
Study 23122211 — intervention group
Group type: COMPARATOR
Intervention: Whole Peanuts (WP)
Number of subjects: 15
Study 23122211 — intervention group
Group type: COMPARATOR
Intervention: Control (no peanuts)
Number of subjects: 15
Study 20371683 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab-CHOP)
Number of subjects: 197
Study 20371683 — intervention group
Group type: COMPARATOR
Intervention: CHOP (conventional chemotherapy)
Number of subjects: 197
Study 18332300 — intervention group
Group type: COMPARATOR
Intervention: Single-dose e-SBI group
Number of subjects: 576
Study 18332300 — intervention group
Group type: COMPARATOR
Intervention: Multidose e-SBI group
Number of subjects: 576
Study 18332300 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (information pamphlet)
Number of subjects: 576
Study 16983932 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine (8-16 mg daily)
Number of subjects: 9
Study 16983932 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5-10 mg daily)
Number of subjects: 9
Study 12657407 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) injection of propofol 2 mg/kg followed by inhalation of sevoflurane 3% (Group P)
Number of subjects: 40
Study 12657407 — intervention group
Group type: COMPARATOR
Intervention: Vital capacity inhalation induction with sevoflurane 8% (Group S)
Number of subjects: 40
Study 10735794 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine 0 mg (Control)
Number of subjects: 60
Study 10735794 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 1.25 mg
Number of subjects: 60
Study 10735794 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 2.5 mg
Number of subjects: 60
Study 10735794 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 3.75 mg
Number of subjects: 60
Study 10735794 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 5 mg
Number of subjects: 60
Study 8959468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine
Number of subjects: 30
Study 8959468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8232485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (250 mg every six hours for 3 days followed by oral prednisone (1 mg per kilogram of body weight) for 11 days)
Number of subjects: 389
Study 8232485 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (1 mg per kilogram for 14 days)
Number of subjects: 389
Study 8232485 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 14 days)
Number of subjects: 389
Study 8232485 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone compared to placebo
Number of subjects: 389
Study 8232485 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone compared to oral prednisone
Number of subjects: 389
Study 8232485 — intervention group
Group type: COMPARATOR
Intervention: MRI signal abnormalities (3 or more lesions)
Number of subjects: 389
Study 2951795 — intervention group
Group type: EXPERIMENTAL
Intervention: Duovent (200 micrograms fenoterol + 80 micrograms ipratropium bromide)
Number of subjects: 12
Study 2951795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms)
Number of subjects: 12
Study 2951795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms)
Number of subjects: 12
Study 2951795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29730666 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine-containing fluoridated dentifrice (AFD)
Number of subjects: 12
Study 29730666 — intervention group
Group type: COMPARATOR
Intervention: Regular fluoridated dentifrice (FD)
Number of subjects: 12
Study 26886163 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Bolus Advisor (ABA) meter (Accu‐Chek Aviva Expert)
Number of subjects: 36
Study 26886163 — intervention group
Group type: COMPARATOR
Intervention: Control phase using a traditional blood glucose meter (Accu‐Chek(®) Aviva Nano)
Number of subjects: 36
Study 24160304 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow speech rate
Number of subjects: 102
Study 24160304 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal speech rate
Number of subjects: 102
Study 24160304 — intervention group
Group type: COMPARATOR
Intervention: Fast speech rate
Number of subjects: 102
Study 23151421 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA (ropivacaine 0.2%+sufentanil)
Number of subjects: 84
Study 23151421 — intervention group
Group type: COMPARATOR
Intervention: PVB (ropivacaine 0.5%)+ITO (sufentanil+morphine)
Number of subjects: 84
Study 20693499 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate (17OHPC)
Number of subjects: 344
Study 20693499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study 18788652 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological sleep therapy for 6 weeks
Number of subjects: 21
Study 18788652 — intervention group
Group type: COMPARATOR
Intervention: Wait list period
Number of subjects: 21
Study 16038599 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine monotherapy
Number of subjects: 0
Study 16038599 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus fluoxetine combination therapy
Number of subjects: 0